Do Different Methods of Modeling Statin Treatment Effectiveness Influence the Optimal Decision?
暂无分享,去创建一个
A. Hofman | E. Steyerberg | M. Hunink | B. Ferket | S. Spronk | M. Hunink | B. J. V. van Kempen | A. Hofman | B. J. van Kempen | M. M. Hunink
[1] J. McMurray,et al. Contribution of modern cardiovascular treatment and risk factor changes to the decline in coronary heart disease mortality in Scotland between 1975 and 1994 , 1999, Heart.
[2] M. Arfan Ikram,et al. The Rotterdam Study: 2012 objectives and design update , 2011, European journal of epidemiology.
[3] P. Tsao,et al. Statin therapy: beyond cholesterol lowering and antiinflammatory effects. , 2002, Circulation.
[4] Neil J Stone,et al. Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines , 2004, Circulation.
[5] Anthony Rodgers,et al. Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk , 2003, The Lancet.
[6] P. Engelfriet,et al. Lipid-lowering treatment for all could substantially reduce the burden of macrovascular complications of diabetes patients in the Netherlands , 2008, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.
[7] S. Grundy,et al. National Cholesterol Education Program Third Report of the National Cholesterol Education Program ( NCEP ) Expert Panel on Detection , Evaluation , and Treatment of High Blood Cholesterol in Adults ( Adult Treatment Panel III ) Final Report , 2022 .
[8] Kirsten Bibbins-Domingo,et al. Projected effect of dietary salt reductions on future cardiovascular disease. , 2010, The New England journal of medicine.
[9] D. Spevack,et al. Effects of statins beyond lipid lowering: potential for clinical benefits. , 2006, International journal of cardiology.
[10] A. Palmer,et al. A health economic model to determine the long-term costs and clinical outcomes of raising low HDL-cholesterol in the prevention of coronary heart disease , 2006, Current medical research and opinion.
[11] D. Huse,et al. Cost-effectiveness of statins. , 1998, The American journal of cardiology.
[12] J Shepherd,et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials , 2009, BMJ : British Medical Journal.
[13] F. Rutten,et al. Clinical benefits and cost-effectiveness of lowering serum cholesterol levels: the case of simvastatin and cholestyramine in The Netherlands. , 1990, The American journal of cardiology.
[14] Michael Pignone,et al. Aspirin, Statins, or Both Drugs for the Primary Prevention of Coronary Heart Disease Events in Men: A CostUtility Analysis , 2006, Annals of Internal Medicine.
[15] L. Coupal,et al. The cost-effectiveness of HMG-CoA reductase inhibitors to prevent coronary heart disease. Estimating the benefits of increasing HDL-C. , 1995, JAMA.
[16] J. Martikainen,et al. Cost-effectiveness of single agent, uptitration and switching statin treatment strategies for lipid lowering in Sweden , 2010, Current medical research and opinion.
[17] L. Goldman,et al. Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease. , 1991, JAMA.
[18] Theo Stijnen,et al. Apparent and Internal Validity of a Monte Carlo–Markov Model for Cardiovascular Disease in a Cohort Follow-up Study , 2006, Medical decision making : an international journal of the Society for Medical Decision Making.
[19] Harlan M. Krumholz,et al. Optimizing Statin Treatment for Primary Prevention of Coronary Artery Disease , 2010, Annals of Internal Medicine.
[20] Kirsten Bibbins-Domingo,et al. Comparing Impact and Cost-Effectiveness of Primary Prevention Strategies for Lipid-Lowering , 2009, Annals of Internal Medicine.
[21] M G Myriam Hunink,et al. Uncertainty and Patient Heterogeneity in Medical Decision Models , 2010, Medical decision making : an international journal of the Society for Medical Decision Making.
[22] L. Goldman,et al. Forecasting coronary heart disease incidence, mortality, and cost: the Coronary Heart Disease Policy Model. , 1987, American journal of public health.
[23] Simon Capewell,et al. The comparative effectiveness of heart disease prevention and treatment strategies. , 2009, American journal of preventive medicine.
[24] W. Elliott. Population Strategies to Decrease Sodium Intake and the Burden of Cardiovascular Disease: A Cost-Effectiveness Analysis , 2011 .
[25] A. Algra,et al. Statin treatment for primary prevention of vascular disease: whom to treat? Cost-effectiveness analysis , 2011, BMJ : British Medical Journal.
[26] H. Gravelle,et al. Discounting in economic evaluations: stepping forward towards optimal decision rules. , 2007, Health economics.
[27] Alicja R Rudnicka,et al. Statin safety: a systematic review. , 2006, The American journal of cardiology.
[28] P. Elwood,et al. Total and HDL cholesterol and risk of stroke. EUROSTROKE: a collaborative study among research centres in Europe , 2002, Journal of epidemiology and community health.
[29] R. Collins,et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2005, The Lancet.
[30] Irina Proskorovsky,et al. Economic evaluation of atorvastatin for prevention of recurrent stroke based on the SPARCL trial. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[31] L. Coupal,et al. Estimating the benefits of modifying risk factors of cardiovascular disease: a comparison of primary vs secondary prevention. , 1998, Archives of internal medicine.
[32] W. Elliott. Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis , 2007 .
[33] J. Mckenney,et al. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). , 2001, JAMA.